CA3253688A1 - TREATMENT METHODS FOR SMALL CELL LUNG CANCER - Google Patents

TREATMENT METHODS FOR SMALL CELL LUNG CANCER

Info

Publication number
CA3253688A1
CA3253688A1 CA3253688A CA3253688A CA3253688A1 CA 3253688 A1 CA3253688 A1 CA 3253688A1 CA 3253688 A CA3253688 A CA 3253688A CA 3253688 A CA3253688 A CA 3253688A CA 3253688 A1 CA3253688 A1 CA 3253688A1
Authority
CA
Canada
Prior art keywords
administered
etoposide
wee1 inhibitor
day
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253688A
Other languages
English (en)
French (fr)
Inventor
Esteban RODRIGO IMEDIO
Luke PIGGOTT
Anne Bellon
Valerie NICOLAS
Anne VASLIN CHESSEX
Lars Damstrup
Claudio Zanna
Original Assignee
Debiopharm International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International SA filed Critical Debiopharm International SA
Publication of CA3253688A1 publication Critical patent/CA3253688A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3253688A 2022-03-07 2023-03-07 TREATMENT METHODS FOR SMALL CELL LUNG CANCER Pending CA3253688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
EP22160556.1 2022-03-07
PCT/EP2023/055751 WO2023170065A1 (en) 2022-03-07 2023-03-07 Methods of treating small cell lung cancer

Publications (1)

Publication Number Publication Date
CA3253688A1 true CA3253688A1 (en) 2023-09-14

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253688A Pending CA3253688A1 (en) 2022-03-07 2023-03-07 TREATMENT METHODS FOR SMALL CELL LUNG CANCER

Country Status (12)

Country Link
US (1) US20260027117A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489756A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509278A (cg-RX-API-DMAC7.html)
KR (1) KR20240158972A (cg-RX-API-DMAC7.html)
CN (1) CN118843466A (cg-RX-API-DMAC7.html)
AR (1) AR128711A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023232376A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253688A1 (cg-RX-API-DMAC7.html)
IL (1) IL315441A (cg-RX-API-DMAC7.html)
MX (1) MX2024010900A (cg-RX-API-DMAC7.html)
TW (1) TW202337469A (cg-RX-API-DMAC7.html)
WO (1) WO2023170065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
CA3043945A1 (en) 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
US20240254123A1 (en) 2021-06-04 2024-08-01 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
IL315441A (en) 2024-11-01
EP4489756A1 (en) 2025-01-15
JP2025509278A (ja) 2025-04-11
WO2023170065A1 (en) 2023-09-14
KR20240158972A (ko) 2024-11-05
TW202337469A (zh) 2023-10-01
CN118843466A (zh) 2024-10-25
US20260027117A1 (en) 2026-01-29
AR128711A1 (es) 2024-06-05
MX2024010900A (es) 2024-09-17
AU2023232376A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
US20240226090A1 (en) Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US20200030302A1 (en) Treating Gastric Cancer Using Combination Therapies Comprising Liposomal Irinotecan, Oxaliplatin, 5-Fluoruracil (and Leucovorin)
JP6805336B2 (ja) 薬学的組み合わせ
US20260027117A1 (en) Methods of treating small cell lung cancer
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
HK40064914A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1248608B (en) Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240829

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250121

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250121

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250131

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228